We are pleased to announce advancements in Alzheimer’s Disease research, stemming from the Phase 3 LUCIDITY trial. Neurology Diagnostics has had the privilege of participating in this trial, and are thrilled to share the compelling results, recently released.
The LUCIDITY Phase 3 trial has brought to light exciting new evidence. Participants receiving the investigational product, ‘HMTM’ experienced a significant reduction in neurofilament light chain blood concentrations (NfL). NfL levels have been closely correlated with the destruction of neurons in the brain. Therefore, lower levels of this protein are a promising sign, showing dramatically slowed progression of Alzheimer's Disease. Additionally, this reduction was closely linked to improvements in memory and other cognitive tests.
The preliminary outcomes of the LUCIDITY trial are highly promising and pave the way for innovative Alzheimer's research. We wish to express our profound appreciation to our collaborating partners, leading experts, and dedicated participants who have contributed to the success of this groundbreaking work.
"This is the first tau aggregation inhibitor to reach the phase 3 stage of development and to produce results like this," noted Dr. Claude Wischik, executive chairman of TauRx Therapeutics, the company behind the new drug. According to Dr. Wischik, the decline in NfL levels suggests a "direct impact on disease pathology."
Our research endeavors continue to expand beyond the compelling findings of the LUCIDITY Phase 3 trial. We are currently planning studies that will delve into Alzheimer’s, Chronic Traumatic Encephalopathies (CTEs), and Parkinson’s disease.
We’re Actively Recruiting: If you know someone impacted by Mild Cognitive Impairment (MCI), Alzheimer's Disease, Multiple Sclerosis (MS) as well as healthy control participants, we invite you to refer them to Neurology Diagnostics.
